Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC# 12-02)

NCT01906385 is registered in ClinicalTrials.gov with Plus Therapeutics as lead sponsor.

NCT NCT01906385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01906385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC# 12-02)
Lead sponsor
Plus Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 3, 2015
Completion date
December 31, 2025
Enrollment
55 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

glioma